Global Medical Cannabis Market Trends, Growth and Size Analysis – Forecast to 2027
出 版 商：Market Research Future
出版日期：2021/08/01
頁 數：146頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Multi-User License)
USD 6,250 (Multi-User License)
Global Medical Cannabis Market– Forecast to 2027
Market Snapshot
As per the MRFR analysis, the global Medical Cannabis Market is expected to register a significant CAGR of 18.14% to surpass USD 33,210.21 million by the end of 2027. Medical marijuana is also called cannabis that has viable remedial properties. The best thing about this plant is that it is used as an unrefined material by various medication associations to make drugs for various medicinal applications. The genuine usage of cannabis for clinical reasons is extending because of its compelling advantages. In any case, it shifts across countries due to the movement, proprietorship, advancement, and clinical finishes paperwork for its use. One more driver of the Medical Cannabis Market is the rising prevalence of continuous contaminations and different illnesses. Clinical Cannabis is ensured and amazing for additional creating signs, for instance, rest issues, pressure, and torture achieved by relentless infections in adults.
The expansion of the Medical Cannabis Market is driven by various elements like augmentation in the usage of cannabis, a rising prevalence of progressing diseases, and considerably more. The growing legitimization of Medical Cannabis in different countries rises to research and improvement of cannabinoids. Nevertheless, growing unlawful usage of Maryjane is depended upon to check the overall Market Outlook advancement. There are various employments of cannabis in the clinical business, which is driving the Medical Cannabis Market development. In the current decade, the use of cannabis has extended even more immediately diverged from various substances. There has been a speedy advancement in cannabis use and is simply climbing in made countries like Western Europe, North America, and Australia.
Segment Overview
The global medical cannabis market is classified into Species, Derivatives, Application, End-use, and route of administration.
Based on species, the market is divided into cannabis Indica, Sativa, and crossbreed.
By derivatives segment, the market has been categorized into cannabidiol (CBD), tetrahydrocannabinol (THC), and much more. In terms of applications, the market has been divided into disease addresses the main classification. By end-use, the market has been classified into the drug business, innovative work communities, and much more. Depending on the route of administration, the market has been divided into oral arrangements and cases, smoking, vaporizers, topical, and others.
Regional Analysis
The Medical Cannabis market has been fragmented dependent on geographics, Asia-Pacific, Americas, Europe, the Middle East, and Africa. The Americas is depended upon to be the greatest market inferable from the rising consumption of clinical cannabis and rising per capita clinical consideration utilization. The market in the Americas has furthermore been stretched out into North America and Latin America, with the North American market divided into the US and Canada. The European Medical Cannabis market has been masterminded in Western Europe and Eastern Europe.
Major Market Players
The major players of the Medical Cannabis market include Canopy Growth, Corporation (Canada), GW Pharmaceuticals PLC (UK), Aurora Cannabis (Canada), Aphria, Inc. (Canada), Maricann Inc. (Canada), Tilray (Canada), Cannabis Sativa Inc. (US), GBSciences Inc. (US), United Cannabis (US), Medical Marijuana, Inc. (US), CanniMed Ltd (Canada), and MediPharm Labs (Canada)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING R&D ACTIVITIES AND FINANCIAL SUPPORT BY VARIOUS PRIVATE AND GOVERNMENT ORGANIZATIONS
4.2.2 RISING OCCURRENCE OF CHRONIC DISEASES AND OTHER MEDICAL CONDITIONS
4.2.3 LEGALIZATION OF MEDICAL CANNABIS IN VARIOUS REGIONS
4.3 RESTRAINTS
4.3.1 ADVERSE EFFECTS ASSOCIATED WITH CANNABIS
4.3.2 STRINGENT GOVERNMENT POLICIES RELATED TO CBD OIL
4.4 OPPORTUNITIES
4.4.1 IMPROVING STATUS OF CANNABIS IN ASIAN AND AFRICAN COUNTRIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 PROCUREMENT OF RAW MATERIALS
5.1.2 R&D
5.1.3 MANUFACTURING
5.1.4 DISTRIBUTION AND SALES
5.1.5 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE MEDICAL CANNABIS MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON DEMAND FOR MEDICAL CANNABIS
5.3.4 IMPACT ON EXISTING REGULATIONS
5.3.5 IMPACT ON RESEARCH
5.3.6 IMPACT ON BUYERS AND SUPPLIERS
6 GLOBAL MEDICAL CANNABIS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 SOLIDS
6.3 DISSOLVABLES/POWDERS
6.4 OIL
6.5 OINTMENTS & CREAMS
7 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVE
7.1 OVERVIEW
7.2 CANNABIDIOL
7.3 TETRAHYDROCANNABINOL
8 GLOBAL MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 INHALATION
8.3 ORAL
8.4 TOPICAL
9 GLOBAL MEDICAL CANNABIS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 PAIN MANAGEMENT
9.2.1 NEUROPATHIC PAIN
9.2.2 CANCER
9.2.3 INFLAMMATORY PAIN
9.3 NEUROLOGICAL HEALTH MANAGEMENT
9.3.1 SCLEROSIS
9.3.2 EPILEPSY
9.3.3 ALZHEIMER’S DISEASE
9.3.4 PARKINSON’S DISEASE
9.3.5 OTHERS
9.4 MENTAL HEALTH MANAGEMENT
9.4.1 POST-TRAUMATIC STRESS DISORDER (PTSD)
9.4.2 DEPRESSION
9.4.3 ANXIETY
9.4.4 OTHERS
10 GLOBAL MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY
11 GLOBAL MEDICAL CANNABIS MARKET, BY REGION
11.1 OVERVIEW
11.2 AMERICAS
11.2.1 NORTH AMERICA
11.2.1.1 US
11.2.1.2 CANADA
11.2.2 LATIN AMERICA
11.3 EUROPE
11.3.1 WESTERN EUROPE
11.3.1.1 GERMANY
11.3.1.2 FRANCE
11.3.1.3 UK
11.3.1.4 ITALY
11.3.1.5 SPAIN
11.3.1.6 REST OF WESTERN EUROPE
11.3.2 EASTERN EUROPE
11.4 ASIA-PACIFIC
11.4.1 JAPAN
11.4.2 AUSTRALIA
11.4.3 SOUTH KOREA
11.4.4 REST OF ASIA-PACIFIC
11.5 MIDDLE EAST & AFRICA
11.5.1 MIDDLE EAST
11.5.2 AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MEDICAL CANNABIS MARKET
12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL MEDICAL CANNABIS MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
12.6.2 MERGER/ACQUISITION
12.6.3 PARTNERSHIP/AGREEMENT
12.6.4 EXPANSION
13 COMPANY PROFILES
13.1 CANOPY GROWTH CORPORATION
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 CANNABIS SATIVA, INC.
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS/SERVICES OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 GW PHARMACEUTICALS PLC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 EMERALD HEALTH THERAPEUTICS
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 TILRAY, INC.
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCT OFFERINGS
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 AURORA CANNABIS INC.
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS/SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 CARA THERAPEUTICS
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS/SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 MEDICAL MARIJUANA, INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS/SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 GB SCIENCES, INC.
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS/SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 CANNDOC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS/SERVICES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 SWOT ANALYSIS
13.10.6 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING R&D ACTIVITIES AND FINANCIAL SUPPORT BY VARIOUS PRIVATE AND GOVERNMENT ORGANIZATIONS
4.2.2 RISING OCCURRENCE OF CHRONIC DISEASES AND OTHER MEDICAL CONDITIONS
4.2.3 LEGALIZATION OF MEDICAL CANNABIS IN VARIOUS REGIONS
4.3 RESTRAINTS
4.3.1 ADVERSE EFFECTS ASSOCIATED WITH CANNABIS
4.3.2 STRINGENT GOVERNMENT POLICIES RELATED TO CBD OIL
4.4 OPPORTUNITIES
4.4.1 IMPROVING STATUS OF CANNABIS IN ASIAN AND AFRICAN COUNTRIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 PROCUREMENT OF RAW MATERIALS
5.1.2 R&D
5.1.3 MANUFACTURING
5.1.4 DISTRIBUTION AND SALES
5.1.5 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE MEDICAL CANNABIS MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON DEMAND FOR MEDICAL CANNABIS
5.3.4 IMPACT ON EXISTING REGULATIONS
5.3.5 IMPACT ON RESEARCH
5.3.6 IMPACT ON BUYERS AND SUPPLIERS
6 GLOBAL MEDICAL CANNABIS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 SOLIDS
6.3 DISSOLVABLES/POWDERS
6.4 OIL
6.5 OINTMENTS & CREAMS
7 GLOBAL MEDICAL CANNABIS MARKET, BY DERIVATIVE
7.1 OVERVIEW
7.2 CANNABIDIOL
7.3 TETRAHYDROCANNABINOL
8 GLOBAL MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 INHALATION
8.3 ORAL
8.4 TOPICAL
9 GLOBAL MEDICAL CANNABIS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 PAIN MANAGEMENT
9.2.1 NEUROPATHIC PAIN
9.2.2 CANCER
9.2.3 INFLAMMATORY PAIN
9.3 NEUROLOGICAL HEALTH MANAGEMENT
9.3.1 SCLEROSIS
9.3.2 EPILEPSY
9.3.3 ALZHEIMER’S DISEASE
9.3.4 PARKINSON’S DISEASE
9.3.5 OTHERS
9.4 MENTAL HEALTH MANAGEMENT
9.4.1 POST-TRAUMATIC STRESS DISORDER (PTSD)
9.4.2 DEPRESSION
9.4.3 ANXIETY
9.4.4 OTHERS
10 GLOBAL MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY
11 GLOBAL MEDICAL CANNABIS MARKET, BY REGION
11.1 OVERVIEW
11.2 AMERICAS
11.2.1 NORTH AMERICA
11.2.1.1 US
11.2.1.2 CANADA
11.2.2 LATIN AMERICA
11.3 EUROPE
11.3.1 WESTERN EUROPE
11.3.1.1 GERMANY
11.3.1.2 FRANCE
11.3.1.3 UK
11.3.1.4 ITALY
11.3.1.5 SPAIN
11.3.1.6 REST OF WESTERN EUROPE
11.3.2 EASTERN EUROPE
11.4 ASIA-PACIFIC
11.4.1 JAPAN
11.4.2 AUSTRALIA
11.4.3 SOUTH KOREA
11.4.4 REST OF ASIA-PACIFIC
11.5 MIDDLE EAST & AFRICA
11.5.1 MIDDLE EAST
11.5.2 AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MEDICAL CANNABIS MARKET
12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL MEDICAL CANNABIS MARKET
12.5 KEY DEVELOPMENT ANALYSIS
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
12.6.2 MERGER/ACQUISITION
12.6.3 PARTNERSHIP/AGREEMENT
12.6.4 EXPANSION
13 COMPANY PROFILES
13.1 CANOPY GROWTH CORPORATION
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS/SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 CANNABIS SATIVA, INC.
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS/SERVICES OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 GW PHARMACEUTICALS PLC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS/SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 SWOT ANALYSIS
13.3.6 KEY STRATEGIES
13.4 EMERALD HEALTH THERAPEUTICS
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS/SERVICES OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 SWOT ANALYSIS
13.4.6 KEY STRATEGIES
13.5 TILRAY, INC.
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCT OFFERINGS
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 AURORA CANNABIS INC.
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS/SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 CARA THERAPEUTICS
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 PRODUCTS/SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 MEDICAL MARIJUANA, INC.
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL OVERVIEW
13.8.3 PRODUCTS/SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 SWOT ANALYSIS
13.8.6 KEY STRATEGIES
13.9 GB SCIENCES, INC.
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 PRODUCTS/SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 CANNDOC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL OVERVIEW
13.10.3 PRODUCTS/SERVICES OFFERED
13.10.4 KEY DEVELOPMENTS
13.10.5 SWOT ANALYSIS
13.10.6 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
